Oric Pharmaceuticals Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Oric Pharmaceuticals will host its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, encouraging prompt stockholder participation and voting.</b>

AI Summary

Oric Pharmaceuticals, Inc. (ORIC) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Oric Pharmaceuticals, Inc. will hold its 2024 Annual Meeting of Stockholders on June 12, 2024. The meeting will be conducted in a virtual format via live audio/video webcast. Stockholders can attend, listen, submit questions, and vote online at www.proxydocs.com/ORIC. A control number from the notice of internet availability or proxy card is required for virtual attendance and voting. The company urges stockholders to vote promptly via Internet, phone, or by returning a signed proxy card.

Why It Matters

For investors and stakeholders tracking Oric Pharmaceuticals, Inc., this filing contains several important signals. The virtual format aims to provide equal participation opportunities for all stockholders, regardless of their location. Stockholder participation is crucial for the company's governance, with a strong emphasis on submitting proxies to ensure shares are represented and voted.

Risk Assessment

Risk Level: low — Oric Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.

Analyst Insight

Stockholders should review the proxy materials and vote their shares for the upcoming annual meeting to ensure their participation in corporate governance.

Key Numbers

• June 12, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders.)
• 8:00 a.m. Pacific Time — Annual Meeting Time (Time of the 2024 Annual Meeting of Stockholders.)

Key Players & Entities

• Oric Pharmaceuticals, Inc. (company) — Registrant and filer of the proxy statement.
• June 12, 2024 (date) — Date of the 2024 Annual Meeting of Stockholders.
• Jacob M. Chacko, M.D. (person) — President and Chief Executive Officer of Oric Pharmaceuticals.
• 2024 (date) — Year of the Annual Meeting of Stockholders.
• South San Francisco, California (location) — Location of Oric Pharmaceuticals' business and mailing address.

FAQ

Industry Context

Oric Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing novel therapies.

Regulatory Implications

The filing is a proxy statement (DEF 14A) filed under the Securities Exchange Act of 1934, a standard regulatory requirement for public companies.

What Investors Should Do

1. Review the proxy statement for details on proposals to be voted on at the Annual Meeting.
2. Vote your shares by the deadline, either online, by phone, or by mail, to ensure your vote is counted.
3. Attend the virtual Annual Meeting on June 12, 2024, to participate in discussions and ask questions.

Key Dates

• 2024-06-12: 2024 Annual Meeting of Stockholders — Key date for stockholder participation and voting.

Year-Over-Year Comparison

This is a routine DEF 14A filing for the annual meeting and does not represent a change from previous filings in terms of core financial or operational data.

Filing Documents

• d755213ddef14a.htm (DEF 14A) — 373KB
• g755213dsp1a.jpg (GRAPHIC) — 4KB
• g755213dsp1b.jpg (GRAPHIC) — 33KB
• g755213dsp1c.jpg (GRAPHIC) — 2KB
• g755213dsp1d.jpg (GRAPHIC) — 2KB
• g755213dsp1e.jpg (GRAPHIC) — 1KB
• g755213dsp1f.jpg (GRAPHIC) — 2KB
• g755213dsp2a.jpg (GRAPHIC) — 1KB
• g755213dsp2b.jpg (GRAPHIC) — 1KB
• g755213g75p02.jpg (GRAPHIC) — 20KB
• g755213g84s61.jpg (GRAPHIC) — 26KB
• 0001193125-24-110069.txt (&nbsp;) — 497KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 26 Processes and Procedures for Compensation Decisions 26 Summary Compensation Table 26 Non-Equity Incentive Plan Compensation 27 Inducement Plan 27 Outstanding Equity Awards at Fiscal Year-End 28 Employment Arrangements with Our Named Executive Officers 29 Equity Compensation Plan Information 31

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 32 RELATED PARTY TRANSACTIONS 36 Indemnification Agreements 36 Related Party Transaction Policy 36 OTHER MATTERS 37 Fiscal Year 2023 Annual Report and SEC Filings 37 Company Website 37 Table of Contents ORIC PHARMACEUTICALS, INC. PROXY STATEMENT FOR 2024 VIRTUAL ANNUAL MEETING OF STOCKHOLDERS To Be Held at 8:00 a.m. Pacific Time on June 12, 2024 This proxy statement and the enclosed form of proxy are being furnished in connection with the solicitation of proxies by our board of directors for use at our 2024 Annual Meeting of Stockholders (and any postponements, adjournments or delays thereof, the Annual Meeting). You will be able to attend the Annual Meeting virtually by visiting www.proxydocs.com/ORIC, where you will be able to listen to the Annual Meeting live, submit questions and vote online by entering the control number on your Notice or proxy card. QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING The information provided in the question and answer format below addresses certain frequently asked questions but is not intended to be a summary of all matters contained in this proxy statement. Please read the entire proxy statement carefully before voting your shares. Why am I receiving these materials? The board of directors is providing these proxy materials to you in connection with its solicitation of proxies for use at ORICs Annual Meeting, which will take place on June 12, 2024. Stockholders are invited to attend the Annual Meeting virtually and are requested to vote on the proposals described in this proxy statement. This proxy What proposals will be voted on at the Annual Meeting? There are two proposals scheduled to be voted on at the Annual Meeting: the election of the

View Full Filing

View this DEF 14A filing on SEC EDGAR